1. Home
  2. GNPX

as 06-21-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Founded: 2009 Country:
United States
United States
Employees: N/A City: AUSTIN
Market Cap: 4.6M IPO Year: 2018
Target Price: $10.00 AVG Volume (30 days): 251.4K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -18.65 EPS Growth: N/A
52 Week Low/High: $2.01 - $42.00 Next Earning Date: 05-14-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

GNPX Daily Stock ML Predictions

Share on Social Networks: